Edition:
United States

Five Prime Therapeutics Inc (FPRX.OQ)

FPRX.OQ on NASDAQ Stock Exchange Global Select Market

36.26USD
27 Mar 2017
Change (% chg)

-- (--)
Prev Close
$36.26
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
166,872
52-wk High
$60.98
52-wk Low
$34.72

Latest Key Developments (Source: Significant Developments)

Five Prime announces fourth quarter and full year 2016 financial results
Thursday, 23 Feb 2017 04:05pm EST 

Five Prime Therapeutics Inc : Five Prime announces fourth quarter and full year 2016 financial results . Q4 loss per share $0.73 .Q4 earnings per share view $-0.57 -- Thomson Reuters I/B/E/S.  Full Article

Five Prime Therapeutics sees 2017 net cash used in operations less than $120 mln-SEC filing
Monday, 9 Jan 2017 10:26am EST 

Five Prime Therapeutics Inc : Expects net cash used in operations for fiscal year 2017 will be less than $120 mln .Five prime therapeutics - expects that cash, cash equivalents and marketable securities as of Dec 31, 2017 will be approximately $300 mln - SEC filing.  Full Article

Five Prime Therapeutics files for potential stock shelf
Thursday, 3 Nov 2016 04:58pm EDT 

Five Prime Therapeutics Inc - :Files for potential stock shelf; size not disclosed - SEC filing.  Full Article

Five Prime reports loss per share of $0.29
Thursday, 3 Nov 2016 04:05pm EDT 

Five Prime Therapeutics Inc : Says collaboration revenue for Q3 of 2016 increased by $0.8 million to $6.7 million . Q3 revenue view $7.5 million -- Thomson Reuters I/B/E/S . Five Prime announces third quarter 2016 results and provides business update . Q3 LOSS PER SHARE $0.72 .Q3 earnings per share view $-0.51 -- Thomson Reuters I/B/E/S.  Full Article

Five Prime announces Q2 2016 results and provides business update
Thursday, 4 Aug 2016 04:05pm EDT 

Five Prime Therapeutics Inc : Five prime announces second quarter 2016 results and provides business update . Q2 earnings per share view $-0.56 -- Thomson Reuters I/B/E/S . Q2 revenue $9.2 million versus $6.3 million . Q2 loss per share $0.49 .Q2 revenue view $6.4 million -- Thomson Reuters I/B/E/S.  Full Article

Five Prime says entered amendment to license agreement with Galaxy Biotech
Friday, 20 May 2016 06:11am EDT 

Five Prime Therapeutics Inc : Entered into an amendment to exclusive license agreement with galaxy biotech, llc - sec filing . Co, galaxy revised milestone definitions, reduced certain milestone payments,added 4 development-related milestone payments .Amount of development-related milestone payments that fiveprime will be obligated to pay was decreased by $0.5 million.  Full Article

Five Prime Therapeutics receives FDA orphan drug designation for FPA008
Wednesday, 13 Jan 2016 09:15am EST 

Five Prime Therapeutics:Says FDA has granted orphan drug designation for FPA008 for the treatment of Pigmented Villonodular Synovitis.  Full Article

Five Prime Therapeutics establishes strategic research collaboration and license agreement with Inhibrx
Wednesday, 15 Jul 2015 04:00pm EDT 

Five Prime Therapeutics:Establishes strategic research collaboration and license agreement with inhibrx for GITR antibodies.Says under the terms of the agreement, Five Prime will pay inhibrx a $10 million license fee.Inhibrx is eligible to receive up to $342.5 million in development, regulatory and commercial milestone payments per therapeutic product.  Full Article

bluebird bio Inc and Five Prime Therapeutics Inc enter into license agreement
Tuesday, 26 May 2015 04:05pm EDT 

bluebird bio Inc and Five Prime Therapeutics Inc:Says they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using Five Prime's human antibodies to an undisclosed cancer target for hematologic malignancies and solid tumors.Says under terms of agreement, Five Prime will provide bluebird bio exclusive rights to novel human antibodies to the target, and bluebird bio will leverage lentiviral gene therapy platform and CAR T capabilities to develop CAR T therapies against the target.Says financial terms of agreement include a $1.5 million upfront payment and subsequent payments to Five Prime, which together could total over $130 million per licensed product if certain development, regulatory, and commercial milestones are achieved.Says Five Prime is also eligible to receive tiered royalties on product sales.  Full Article

More From Around the Web